Even as Mumbai`s monsoon season is underway, the importance of eating the right foods is also necessary because it can also ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planne ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...

KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive immunity to treat solid tumors, today announced that ...

Highly pathogenic avian influenza viruses like H5N1, H5N6, and H7N9 pose an evolving global threat due to their capacity to infect birds, mammals, and occasionally humans, with sporadic outbreaks and ...

Rheumatic diseases are complex multisystem, immune-mediated disorders encompassing conditions like rheumatoid arthritis, ...

Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Clear signs of immune activation: ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune ...